Israeli-German research produces bionic liver-on-a-chip model with aim to replace animal studies

"This new technology provides exceptional insight into drug toxicity, and could in fact transform current practice."

By
August 17, 2015 21:59
2 minute read.
technology

CHIP-BASED artificial organs such as this ‘liver,’ could one day replace animal experiments, researchers hope.. (photo credit: HEBREW UNIVERSITY)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Instead of carrying out experimentation on animals to determine whether a drug or cosmetic is safe for humans, the Hebrew University of Jerusalem and Germany’s Fraunhofer Institute for Cell Therapy and Immunology have joined together to successfully create a liver-on-chip device that mimics human physiology.

While safety evaluation is a critical part of drug and cosmetic development, there has been a growing understanding in recent years that animal experiments do not always accurately predict the human response.

Be the first to know - Join our Facebook page.


The main problem in replacing animal experiments with other models is that human cells rarely survive more than a few days outside the body. The Israeli-German research therefore fills an urgent need. “The liver organs we created were less than a millimeter in diameter and survived for more than a month,” Prof. Yaakov Nahmias, the study’s lead author and director of Hebrew University’s Alexander Grass Center for Bioengineering said.

While other groups showed similar results, the breakthrough came when the groups added nanotechnology-based sensors to the mix, Nahmias said. “We realized that because we are building the organs ourselves, we are not limited to biology and could introduce electronic and optical sensors to the tissue itself. Essentially we are building bionic organs on a chip.” The addition of nanotechnology-based optoelectronic sensors to the living tissues enabled the group to identify a new mechanism of acetaminophen (Tylenol or Excedrin) toxicity.

“Because we placed sensors inside the tissue, we could detect small and fast changes in cellular respiration that nobody else could,” Nahmias said. “Suddenly nothing we saw made sense.” The researchers discovered that acetaminophen blocked respiration much faster and at a much lower dose than previously believed. The current understanding was that acetaminophen broke down into a toxic compound, called NAPQI, before damaging cells.

As the liver could naturally deactivate NAPQI, damage was thought to occur only at high doses and in cases of diseased or compromised liver function.

The current study, released online in the leading journal Archives of Toxicology, turns half a century of research on its head. The authors found that acetaminophen itself can stop cellular respiration in minutes, even in the absence of NAPQI, explaining much of the side-effects of the drug.

JPOST VIDEOS THAT MIGHT INTEREST YOU:


“This is a fascinating study”, said Prof. Oren Shibolet, head of the liver unit at Tel Aviv Sourasky Medical Center and one of the leading experts on drug-induced liver injury (who was not part of the original study). “We knew that acetaminophen can cause nephrotoxicity [toxicity to the kidneys] as well as rare-but-serious skin reactions, but up until now, we didn’t really understand the mechanism of such an effect. This new technology provides exceptional insight into drug toxicity, and could in fact transform current practice.”

The results mark the first discovery of a new toxicity mechanism using the newly emerging human-on-a-chip technology, suggesting that the development of alternative models for animal testing will soon follow. The global market for the technology has shown a double-digit annual growth rate in the last three years and is predicted to grow to $17 billion by 2018.

Yissum, Hebrew University’s Research & Development Company and Fraunhofer, Europe’s largest application-oriented research organization, submitted a joint provisional patent application earlier this year and are actively seeking industrial partners.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Health Minister Yakov Litzman  received the annual flu shot by Prof. Itamar Grotto in a school in Te
November 4, 2018
Measles spreads across Israel with 1,334 new patients diagnosed

By JERUSALEM POST STAFF